PRESENTATION

Q4 2024 — Results presentation

Q4 2024PDF · 31 pages8.0 MB


-- 1 of 31 --

4th Quarter 2024
Earnings Call
January 22, 2025

-- 2 of 31 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including
technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to
successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply
chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by
government agencies; and the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc. A further list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding
Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks
only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 31 --

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and
commercialize for a broad range of indications
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and
Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS)
Infectious Diseases
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Cardiovascular/
Metabolism/Other
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab
A/S relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Oncology
UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan	Pulmonary Hypertension
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo ® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding
and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-
clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176),
EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the
European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health
and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola
was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the
Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA
invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract
Number HHSN272200800056C.
Global Public Health
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 31 --

CEO Remarks
Enterprise highlights
Sales performance and earnings review
Capital allocation and guidance
Q&A
Agenda
1
2
3
4
5
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 5 of 31 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 31 --

~$50 billion 1
invested in R&D
and M&A
Disciplined
decisions to
exit lower-
priority
businesses
Operating in
high-unmet need,
high-growth,
high-innovation
segments
Positioned for
5-7%2,3 growth
through 2030
and beyond
2024: Year of progress and continued transformation
1 Includes the announcement of the planned acquisition of Intra-Cellular Therapies Inc. on January 13, 2025
2 Represents operational sales; Non-GAAP financial measure; excludes the impact of translational currency
3 Based on risk-adjusted sales projections

-- 7 of 31 --

Innovating across the entire patient pathway
8
Multiple
myeloma Heart
recovery Mental
health Inflammatory
bowel
disease
Monoclonal
antibody
CAR-T
Bi-specific
antibodies
Impella
heart pumps
Minimally invasive
interatrial shunt
Oral and
long-acting
injectables
Once-daily
oral*
Nasal spray
*Pending closing of Intra-Cellular Therapies Inc planned acquisition
Targeted
oral peptide
Co-antibody
therapeutic
Monoclonal
antibodies
icotrokinra
JNJ-4804

-- 8 of 31 --

Delivering on our
commitments and fortifying
our future

-- 9 of 31 --

Jessica Moore
Vice President,
Investor Relations

-- 10 of 31 --

% Change
Q4 2023	Q4 2024	Regional sales results 	Operational1
Reported
10.0%	10.0%	$12.0	$13.2	U.S.
(0.2)	(0.8)	5.0	4.9	Europe
17.6	(2.7)	1.2	1.1
Western Hemisphere
(ex U.S.)
0.9	0.1	3.3	3.3	Asia-Pacific, Africa
2.5	(0.7)	9.4	9.3	International
6.7%	5.3%	$21.4	$22.5	Worldwide (WW)
Dollars in billions
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded
4th Quarter 2024 sales
11

-- 11 of 31 --

$22.5 $21.4
$4.9 $5.6
(10.9)%; (10.5)%1
$2.043 $2.29
Dollars in billions, except EPS
Reported %; Operational %1
Sales
Adjusted earnings2 	Adjusted EPS 2
5.3%; 6.7% 1 (17.0)%
GAAP earnings
$3.4
$4.1
(11.1)%
(17.1)%
$1.413
$1.70
Q4 2024 	Q4 2023 	Q4 2024 	Q4 2023 	Q4 2024 	Q4 2023
Q4 2024 	Q4 2023 	Q4 2024 	Q4 2023
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
3 Includes $(0.22) due to acquired IPR&D charges related to V-Wave acquisition
4th Quarter 2024 financial highlights
GAAP EPS
12

-- 12 of 31 --

% Change
2023	2024	Regional sales results1 Operational2
ex COVID-19 Vaccine
Operational2
Reported
8.3%	8.3%	8.3%	$46.4	$50.3	U.S.
4.1	(0.6)	(1.0)	20.4	20.2	Europe
20.4	20.4	3.6	4.5	4.7
Western Hemisphere
(ex U.S.)
2.3	2.3	(1.2)	13.8	13.6	Asia-Pacific, Africa
5.5	2.9	(0.5)	38.7	38.5	International
7.0%	5.9%	4.3%	$85.2	$88.8	Worldwide (WW)
Dollars in billions
1 Reflects continuing operations of Johnson & Johnson
2 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded 	13
Full year 2024 sales

-- 13 of 31 --

1 Results have been recast to reflect the continuing operations of Johnson & Johnson 	4 Excluding COVID-19 Vaccine
2 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	5 Includes $(0.67) due to acquired IPR&D charges on various transactions throughout the year
3 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
0.6%; 0.7% 2
$9.985 $9.92
Dollars in billions, except EPS
Reported %; Operational %2
Sales
Adjusted earnings3 	Adjusted EPS 3
4.3%; 5.9% 2 , 7.0% 2,4 5.6%
$14.1 $13.3
(4.6)%
11.3%
$5.795
$5.20
2024 	2023
$24.2 $25.4
2024 	2023 	2024 	2023
$88.8 $85.2
2024 	2023 	2024 	2023
Full year 2024 financial highlights1
GAAP EPS
14
GAAP earnings

-- 14 of 31 --

Immunology
$4,238
Infectious Diseases
$774
Neuroscience
$1,775
Oncology
$5,497
CVM/Other
$957
PH
$1,092
■ Reported growth 	■ Operational growth1
$14,332
4.4%, 6.5% 3
WW sales $MM
Key drivers of operational performance1
• 	DARZALEX increase driven by continued strong share gains and market growth
• 	ERLEADA increase driven by continued share gains and market growth
• 	CARVYKTI increase driven by continued share gains and capacity expansion
• 	TECVAYLI growth driven by ongoing launch
• 	Growth in Other Oncology driven by launches of RYBREVANT and TALVEY
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA competitive pressures
Oncology
• 	TREMFYA increase due to market growth and share gains, partially offset by unfavorable
patient mix and inventory dynamics
• 	SIMPONI/SIMPONI ARIA driven by MSD5 return of rights, market growth, and favorable mix
• 	STELARA decline driven by inventory dynamics and share loss primarily due to EU biosimilar
entrants, partially offset by market growth and net patient mix
• 	REMICADE decline due to biosimilar competition, partially offset by MSD5 return of rights
Immunology
• 	SPRAVATO growth driven by ongoing launch and increased physician and patient demand
• 	Growth partially offset by declines in Other Neuroscience due to EU SPINRAZA tender loss
Neuroscience
• 	OPSUMIT growth driven by market growth and share gains, partially offset by inventory
dynamics in the U.S.
• 	UPTRAVI growth driven by market growth, favorable patient mix, and share gains
• 	Growth in Other PH driven by OPSYNVI
Pulmonary
Hypertension (PH)
• 	XARELTO growth driven by favorable patient mix
Cardiovascular /
Metabolism / Other
(CVM/Other)
• 	Declines across the portfolio including COVID-19 Vaccine	Infectious Diseases
Adjusted operational sales 2,3 : WW: 6.7%, U.S. 11.2%, Int’l 0.0%
Innovative Medicine highlights – 4th quarter 2024
WW 4.4%, U.S. 11.1%, Int’l (5.1)%	Reported:
WW 6.5%, U.S. 11.1%, Int’l (0.3)%	Operational 1,3:
14.3%, 14.8%
7.4%, 8.7%
19.0%, 21.3%
(9.2)%, (8.4)%4 	(7.8)%, (6.1)%
Strong operational growth 1 of 6.5% 3 driven primarily by Oncology
(1.5)%, (0.3)%
15
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	4 Including COVID-19 Vaccine
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	5 MSD: Merck, Sharp, & Dohme
3 Excluding COVID-19 Vaccine 	Note: Values may be rounded

-- 15 of 31 --

Key drivers of operational performance1
• 	Electrophysiology: Driven by global procedure growth, new product performance (QDOT, NUVISION,
OPTRELL, and OUS VARIPULSE), and commercial execution, partially offset by competitive PFA pressures in
ablation catheters in the U.S. and volume-based procurement (VBP) in China
• 	Abiomed: Strength from all major commercialized regions driven by continued strong adoption of Impella 5.5
and Impella RP, partially offset by near-term impacts related to the IV saline shortage
• 	Shockwave: Acquired May 31, 2024
Cardiovascular 3
All platforms impacted by the previously announced Orthopaedics Transformation
• 	Hips: Reflects continued portfolio strength (primarily in the Anterior approach), OUS inventory dynamics, and
go to market changes in EMEA
• 	Trauma: Growth driven by continued adoption of recently launched products, procedure growth, commercial
execution, and timing of capital placements in the U.S.
• 	Knees: Strong growth driven by procedures, continued strength of the ATTUNE portfolio (Cementless &
Medial Stabilized), pull through related to the VELYS Robotic assisted solution, go to market changes in EMEA,
and OUS inventory dynamics, partially offset by OUS tender timing and timing of holidays in the U.S.
• 	Spine, Sports & Other: Reflects competitive pressures and VBP, partially offset by growth in
Craniomaxillofacial and Shoulders, and OUS market growth and inventory dynamics
• 	Spine: ~ -1% WW, ~ -3% U.S., ~ +2% OUS
Orthopaedics
• 	Advanced
• 	Biosurgery: ~ +8% Driven by continued strength of the portfolio (SURGIFLO, SURGICEL Powder,
Evarrest, and VISTASEAL) and commercial execution, partially offset by U.S. supply challenges and VBP
• 	Endocutters: ~ -5%, Primarily due to competitive pressures, Bariatric procedure softness, and VBP,
partially offset by success of recently launched products (ECHELON 3000)
• 	Energy: ~ -5%, Due to competitive pressures, Harmonic market decline in the U.S., and OUS tender timing
• 	General: Growth primarily due to technology penetration and upgrades within our differentiated Wound
Closure portfolio (Barbed & PLUS Sutures) and price adjustments associated with hyperinflation, partially
offset by the Acclarent divestiture
Surgery
• 	Contact Lenses/Other: Growth driven by trade inventory dynamics, price actions, continued strong
performance of the ACUVUE OASYS 1-Day family (including recent launch of OASYS MAX 1-Day), and lapping
of prior year impacts from Russia sanctions
• 	Surgical: Reflects continued strength of recent innovation (TECNIS PureSee & TECNIS Eyhance) and
commercial execution, partially offset by competitive pressures in the U.S.
Vision
Adjusted operational sales 2: WW 4.6%, U.S. 3.3%, Int’l 6.1%
Orthopaedics
$2,315
Surgery
$2,507
Vision
$1,303
Cardiovascular3
$2,062
■ Reported growth 	■ Operational growth1
$8,188
6.7%, 7.6%
WW sales $MM
Strong operational growth 1 of 7.6% due to commercial execution, innovation, and Shockwave
WW 6.7%, U.S. 7.6%, Int’l 5.8%	Reported:
WW 7.6%, U.S. 7.6%, Int’l 7.6%	Operational 1 :
23.6%, 24.2%
7.9%, 9.1%
2.1%, 2.5%
(0.9)%, 0.4%
MedTech highlights – 4th quarter 2024
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
3 Previously referred to as Interventional Solutions
Note: Values may be rounded 	16

-- 16 of 31 --

%
Increase
(Decrease)
2023	2024
% to Sales	Amount	% to Sales	Amount
5.3	100.0	$21,395	100.0	$22,520	Sales to customers
4.9	31.8	6,798	31.6	7,128	Cost of products sold (COGS)
5.4	68.2	14,597	68.4	15,392	Gross Profit
11.1	27.1	5,810	28.6	6,453	Selling, marketing and administrative expenses (SM&A)
18.3	20.9	4,480	23.5	5,298	Research and development expense (R&D)
0.3	58	0.1	17	In-process research and development impairments (IPR&D)
(1.0)	(212)	(0.6)	(144)	Interest (income) expense, net
(2.0)	(421)	(0.7)	(161)	Other (income) expense, net
0.3	56	0.2	42	Restructuring
(19.5)	22.6	4,826	17.3	3,887	Earnings before provision for taxes on income
(34.3)	3.3	694	2.1	456	Provision for taxes on income
(17.0)	19.3	$4,132	15.2	$3,431	Net Earnings from Continuing Operations
(83)	-	Net Earnings / (loss) from Discontinued Operations, net of tax
$4,049	$3,431	Net Earnings
-
(17.1)	$1.70	$1.41	Net earnings per share (Diluted) from Continuing Operations
($0.03)	-	Net earnings / (loss) per share (Basic) from Discontinued Operations*
2,430.7	2,427.1	Average shares outstanding (Diluted)
14.4%	11.7%	Effective tax rate from Continuing Operations
.
Adjusted earnings from Continuing Operations before provision for taxes and net earnings 1
(13.1)	29.2	$6,237	24.1	$5,421	Earnings before provision for taxes on income from Continuing Operations
(11.1)	26.0	$5,562	22.0	$4,946	Net earnings from Continuing Operations
(10.9)	$2.29	$2.04	Net earnings per share (Diluted) from Continuing Operations
10.8%	8.8%	Effective tax rate from continuing operations
* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
4th Quarter 2024
(Unaudited; Dollar and shares in millions except per share figures)
Condensed consolidated statement of earnings
17

-- 17 of 31 --

$0.9 $1.2
$4.7
$5.1
2024 	2023
Innovative Medicine
MedTech
Expenses not allocated to segments
Q4 2023	Q4 2024
37.4%	32.5%	Innovative Medicine
15.5%	10.8%	MedTech
29.2%	24.1%	Total
% to sales
Adjusted income before tax by segment 1
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
2 Estimated as of 1/22/2025
Note: Values may be rounded
4th Quarter 2024
$6.2B
$5.4B
($0.1)
2
18
($0.1)
3 Includes V-Wave acquired IPR&D expense worth (660) basis points and Laminar
milestone expense worth (340) basis points
4 Includes Laminar acquired IPR&D expense worth (510) basis points
4	3

-- 18 of 31 --

$6.9 	$7.2
$22.5 $23.0
2024 	2023
Innovative Medicine
MedTech
Expenses not allocated to segments
FY 2023	FY 2024
42.0%	39.4%	Innovative Medicine
23.7%	21.6%	MedTech
35.0%	32.6%	Total
% to sales
Adjusted income before tax by segment1,2
1 Reflects continuing operations of Johnson & Johnson
2 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
3 Estimated as of 1/22/2025
Note: Values may be rounded
Full year 2024
$29.8B$29.0B
($0.4) 3
19
($0.4)
4 Includes NM26 Bi-specific Antibody acquired IPR&D expense worth (220) basis points
5 Includes V-Wave acquired IPR&D expense worth (170) basis points and Laminar
milestone expense worth (90) basis points
6 Includes Laminar acquired IPR&D expense worth (130) basis points and favorable
intellectual property litigation settlement worth 80 basis points
5
4
6
Taking into consideration the items below, Adjusted income before tax
for the enterprise is relatively flat

-- 19 of 31 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 20 of 31 --

Capital allocation
Organic growth business needs
Free cash flow 1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q4 2024	Dollars in billions
$25
Cash and marketable
securities
($37)	Debt
($12)	Net debt
~$20	Free cash flow 1,2
Full year 2024:
$17.2B invested in R&D
$11.8B in dividends paid
to shareholders;
Note: Values may be rounded
1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 Estimated as of January 22, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 Includes announcement of the planned acquisition of Intra-Cellular Therapies Inc. on January 13, 2025, as well as acquired IPR&D expenses associated with the NM26 Bi-specific antibody and V-wave acquisitions
Note: Values may be rounded
Capital allocation strategy
21
~$32B 3 deployed, announced, or
committed in strategic, inorganic
growth opportunities

-- 21 of 31 --

Operational 2 sales guidance of 3% and adjusted operational EPS2,4 of 8.7% (midpoints)
Comments	January 2025
Midpoint of 2.5%	2.0% - 3.0%	Adjusted operational sales1,2,6
Midpoint of $91.3B or 3.0%
$90.9B - $91.7B
2.5% - 3.5%
Operational sales2,6
Midpoint of $89.6B or 1.0%
FX impact of ($1.7B) or (2.0%)
$89.2B - $90.0B
0.5% - 1.5%
Estimated reported sales 3,6
Operating spend management and reduced acquired IPR&D expenses	Increase of ~300 bps
Adjusted pre-tax
operating margin4,5
Reduced employee benefit income, non-recurring monetization of
royalty rights, and loss of Kenvue dividend
$0.9 - $1.1 billion	Net other income 4
Higher debt levels and reduced interest rates on cash	$0 - ($100) million	Net interest expense / (income)
Based on current tax laws and anticipated geographic income mix	16.5% - 17.0%	Effective tax rate4
Midpoint of $10.85 or 8.7%
$10.75 - $10.95
7.7% - 9.7%
Adjusted EPS (operational)2,4
Midpoint of $10.60 or 6.2%
FX impact of ($0.25) or (2.5%)
$10.50 - $10.70
5.2% - 7.2%
Adjusted EPS (reported) 3,4
2025 P&L guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: January 2025 = $1.04; Euro Spot Rate: January 2025 = $1.04 	6 Excludes COVID-19 Vaccine
Note: Values may be rounded 	22
Excludes impact from the recently announced acquisition of Intra-Cellular Therapies Inc. (ITCI)

-- 22 of 31 --

Anticipated impact from planned ITCI acquisition	January 2025 excl. ITCI
2.0% - 3.0%	Adjusted operational sales1,2,6
Approx. $0.7B or 0.8%
$90.9B - $91.7B
2.5% - 3.5%
Operational sales2,6
Approx. $0.7B or 0.8%
$89.2B - $90.0B
0.5% - 1.5%
Estimated reported sales 3,6
Increase of ~300 bps
Adjusted pre-tax
operating margin4,5
$0.9 - $1.1 billion	Net other income 4
Approx. $500 million expense	$0 - ($100) million	Net interest expense / (income)
16.5% - 17.0%	Effective tax rate4
($0.30) – ($0.35)
$10.75 - $10.95
7.7% - 9.7%
Adjusted EPS (operational)2,4
($0.30) – ($0.35)
$10.50 - $10.70
5.2% - 7.2%
Adjusted EPS (reported) 3,4
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: January 2025 = $1.04; Euro Spot Rate: January 2025 = $1.04 	6 Excludes COVID-19 Vaccine
Note: Values may be rounded 	23
Will be influenced by the transaction close date and borrowing rates; assumed to close early in the second quarter
Intra-Cellular Therapies Acquisition Considerations

-- 23 of 31 --

Innovative
Medicine
• 	Expect more pronounced impact from newly launched products as the year progresses
• 	STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy1
• 	Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year
• 	Expect acceleration of newly launched products; full benefit of Shockwave acquisition through May
• 	Lapping of prior year quarterly comparators to be considered
• 	Normalized procedure volume and seasonality
2025 Phasing Considerations
MedTech
• 	One-time items impacting EPS last year:
• 	Benefit of Kenvue dividend in the first two quarters
• 	Higher interest income prior to Shockwave acquisition closure in May
• 	Monetization of royalty rights experienced in Q3
• 	IPR&D expense associated with NM-26 Bi-specific antibody acquisition (Q3) and V-Wave acquisition (Q4)
• 	Expect second half earnings per share growth higher than the first half
P&L
24
Anticipate second half operational sales growth higher than the first half
1 Once faced with material biosimilar competition, with the additive impact of Part D re-design

-- 24 of 31 --

Innovative Medicine
Anticipated 2025 milestones1 driving long-term value creation
MedTech
25
TREMFYA Sub-Q in CD
nipocalimab in gMG
RYBREVANT Sub-Q
TAR-200 NMIBC
icotrokinra in PsO and UC
RYBREVANT OS
Impella ECP
OTTAVA progression
Advancements across Cardiovascular
(incl. Electrophysiology, Heart
Recovery, and Circulatory Restoration)
1 List above is not inclusive of all 2025 anticipated milestones
Sub-Q: Subcutaneous; CD: Crohn’s Disease; gMG: Generalized Myasthenia gravis; NMIBC: Non-muscle invasive bladder cancer; PsO: Psoriasis; UC: Ulcerative colitis; OS: Overall survival

-- 25 of 31 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 26 of 31 --

Slide footer goes here if required 	27

-- 27 of 31 --

Immunology
$17,828Infectious Diseases
$3,396
Neuroscience
$7,115
Oncology
$20,781
CVM/Other
$3,562
PH
$4,282
■ Reported growth 	■ Operational growth 1
$56,964
4.0%, 7.5%3
WW sales $MM
WW 4.0%, U.S. 9.0%, Int’l (2.5)%	Reported:
WW 7.5%, U.S. 9.0%, Int’l 5.5%	Operational 1,3:
Orthopaedics
$9,158
Surgery
$9,845
Vision
$5,146
Cardiovascular5
$7,707
■ Reported growth 	■ Operational growth 1
$31,857
4.8%, 6.2%
WW sales $MM
Innovative Medicine and MedTech FY 2024 Sales
(3.0)%, (2.6)%
12.3%, 14.1%
17.7%, 19.8%
(23.1)%, (22.7)% 4 (1.2)%, 0.4%
Innovative Medicine
(0.4)%, 1.3%
28
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	3 Excluding COVID-19 Vaccine
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	4 Including COVID-19 Vaccine
Note: Values may be rounded 	5 Previously referred to as Interventional Solutions
Adjusted operational sales2,3: WW: 7.6%, U.S. 9.1%, Int’l 5.7%
MedTech
Adjusted operational sales2 : WW 4.7%, U.S. 4.8%, Int’l 4.7%
21.4%, 22.8%
1.5%, 3.0%
2.4%, 3.0%
(1.9)%, 0.1%
Strong full year 2024 operational sales growth 1 across Innovative Medicine and MedTech
WW 4.8%, U.S. 6.9%, Int’l 2.6%	Reported:
WW 6.2%, U.S. 6.9%, Int’l 5.4%	Operational 1:

-- 28 of 31 --

%
Increase
(Decrease)
2023	2024
% to Sales	Amount	% to Sales	Amount
4.3	100.0	$85,159	100.0	$88,821	Sales to customers
3.5	31.2	26,553	30.9	27,471	Cost of products sold (COGS)
4.7	68.8	58,606	69.1	61,350	Gross Profit
6.3	25.2	21,512	25.7	22,869	Selling, marketing and administrative expenses (SM&A)
14.2	17.7	15,085	19.4	17,232	Research and development expense (R&D)
0.4	313	0.2	211	In-process research and development impairments (IPR&D)
(0.6)	(489)	(0.6)	(577)	Interest (income) expense, net
7.8	6,634	5.3	4,694	Other (income) expense, net
0.6	489	0.3	234	Restructuring
10.8	17.7	15,062	18.8	16,687	Earnings before provision for taxes on income
51.0	2.1	1,736	3.0	2,621	Provision for taxes on income
5.6	15.6	$13,326	15.8	$14,066	Net Earnings from Continuing Operations
21,827	-	Net Earnings from Discontinued Operations, net of tax
$35,153	$14,066	Net Earnings
-
11.3	$5.20	$5.79	Net earnings per share (Diluted) from Continuing Operations
$8.52	-	Net earnings per share (Diluted) from Discontinued Operations
2,560.4	2,429.4	Average shares outstanding (Diluted)
11.5%	15.7%	Effective tax rate from Continuing Operations
.
Adjusted earnings from Continuing Operations before provision for taxes and net earnings 2
(2.8)	35.0	$29,811	32.6	$28,979	Earnings before provision for taxes on income from Continuing Operations
(4.6)	29.8	$25,409	27.3	$24,242	Net earnings from Continuing Operations
0.6	$9.92	$9.98	Net earnings per share (Diluted) from Continuing Operations
14.8%	16.3%	Effective tax rate from continuing operations
1 Reflects continuing operations of Johnson & Johnson
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
Full year 2024
(Unaudited; Dollar and shares in millions except per share figures)
Condensed consolidated statement of earnings1
29

-- 29 of 31 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
OPSUMIT (macitentan) 	 	US DARZALEX (daratumumab) 	 	US TREMFYA (guselkumab) 	 	US RYBREVANT (amivantamab) 	 nipocalimab 	 nipocalimab
 	EU Pediatric Pulmonary Arterial
Hypertension (TOMORROW)
 	EU Frontline multiple myeloma
transplant eligible (PERSEUS)
Pediatric Juvenile Psoriatic
Arthritis
 	EU Subcutaneous (PALOMA-3) 	Generalized Myasthenia Gravis 	Sjogren's Disease (DAHLIAS)
 	US
OPSYNVI/YVANCI
(macitentan/tadalafil STCT) 	 	US
CARVYKTI (ciltacabtagene
autoleucel) 	 	US TREMFYA (guselkumab) 	 	US DARZALEX (daratumumab) 	 seltorexant 	
TAR-200 (RIS/gemcitabine plus
cetrelimab)
 	EU Pulmonary Arterial Hypertension 	 	EU Relapsed Refractory multiple
myeloma w/1-3 PL (CARTITUDE-
4)
 	EU Ulcerative Colitis (QUASAR) 	 	EU Frontline multiple myeloma
transplant eligible (PERSEUS)
Adjunctive treatment for major
depressive disorder with
insomnia symptoms
Non Muscle Invasive Bladder
Cancer (SunRISe-1)
 	US EDURANT (rilpivirine) 	 	US RYBREVANT (amivantamab) 	 	US TREMFYA (guselkumab) 	 	US DARZALEX (daratumumab) 	 SPRAVATO (esketamine) 	 TECVAYLI (teclistamab)
 	EU HIV pediatric 2-12 year old 	 	EU Frontline Non Small Cell Lung
Cancer in combination with
chemotherapy (PAPILLON)
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
 	EU Frontline multiple myeloma
transplant ineligible (CEPHEUS)
Treatment Resistant Depression
monotherapy (TRD4005)
Trasplant-eligible Newly
Diagnosed Multiple Myeloma
(MajesTEC-5)
 US^ BALVERSA (erdafitinib) 	 	US RYBREVANT 	 	US TREMFYA (guselkumab) 	 	US DARZALEX (daratumumab) 	 TREMFYA (guselkumab)
 	EU Urothelial Cancer (THOR) 	 	EU Non Small Cell Lung Cancer 2L
(MARIPOSA-2)
 	EU Crohn's Disease Subcutaneous
Induction (GRAVITI)
 	EU Smoldering Multiple Myeloma
(AQUILA)
Crohn's Disease Subcutaneous
Induction (GRAVITI)
 	US TREMFYA (guselkumab) 	 	US RYBREVANT / LAZCLUZE 	 	US SIMPONI (golimumab) 	IMBRUVICA (ibrutinib) 	 TREMFYA (guselkumab)
Ulcerative Colitis (QUASAR) 	 	EU Non Small Cell Lung Cancer
(MARIPOSA)
 	EU Pediatric Ulcerative Colitis 	 	EU Frontline MCL (Triangle) 	Crohn's Disease (GALAXI)
STELARA (ustekinumab) 	 	US OPSUMIT (macitentan) 	 TREMFYA (guselkumab)
 	EU Pediatric Crohn's Disease 	Pediatric Pulmonary Arterial
Hypertension (TOMORROW)
Ulcerative Colitis (QUASAR)
 	US TREMFYA (guselkumab) 	UPTRAVI (selexipag) 	 DARZALEX (daratumumab)
Pediatric Psoriasis 	 	EU Pediatric Pulmonary Arterial
Hypertension (SALTO)
Frontline multiple myeloma
transplant ineligible (CEPHEUS)
 	US TREMFYA (guselkumab) 	 	US
SPRAVATO (esketamine)
monotherapy 	 DARZALEX (daratumumab)
 	EU Crohn's Disease (GALAXI) 	Treatment Resistant Depression
(TRD4005)
Smoldering Multiple Myeloma
(AQUILA)
 	US nipocalimab 	 DARZALEX (daratumumab)
 	EU Generalized Myasthenia Gravis 	Amyloidosis (ANDROMEDA)
REKAMBYS 	 RYBREVANT (amivantamab)
 	EU HIV Adolescents 	Subcutaneous (PALOMA-3)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2024*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. ^ BALVERSA US Full Approval
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these
programs and assets and does not guarantee continued investment. This information is as of "&Date&" to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= Achieved
1 In order to be on key events clinical presentation, data must be presented at a major medical meeting. ^ BALVERSA US Full Approval
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these
programs and assets and does not guarantee continued investments. This information is as of January 22, 2025 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 30 of 31 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
US SIMPONI (golimumab) 	US nipocalimab 	US nipocalimab 	US
TAR-200 (RIS/gemcitabine plus
cetrelimab) 	AKEEGA (niraparib/abiraterone)
TAR-200 (RIS/gemcitabine plus
cetrelimab)
EU Pediatric Ulcerative Colitis
(PURSUIT 2)
EU Generalized Myasthenia Gravis
(Vivacity MG3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Non Muscle Invasive Bladder
Cancer (SunRISe-1)
M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
US TREMFYA (guselkumab) 	 	US SPRAVATO (esketamine) 	TREMFYA (guselkumab) 	US aticaprant 	RYBREVANT / LAZCLUZE 	RYBREVANT (amivantamab)
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Treatment Resistant Depression
monotherapy (TRD4005)
EU Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Adjunctive Treatment for Major
Depressive Disorder with
Non Small Cell Lung Cancer
(MARIPOSA Final OS)
Head and Neck Cancer (ORIGAMI-4)
US TREMFYA (guselkumab) 	US DARZALEX (daratumumab) 	US TREMFYA (guselkumab) 	TREMFYA (guselkumab) 	TALVEY + TECVAYLI
EU Crohn's Disease Subcutaneous
Induction (GRAVITI)
EU Smoldering Multiple Myeloma
(AQUILA)
Psoriatic Arthritis Structural
Damage (APEX)
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Multiple Myeloma
Relapsed/Refractory (RedirecTT-1)
US TREMFYA (guselkumab) 	US DARZALEX (daratumumab) 	TREMFYA (guselkumab) 	TREMFYA (guselkumab) 	RYBREVANT (amivantamab)
Pediatric Psoriasis
(PROTOSTAR)
EU Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis Structural
Damage (APEX)
Colorectal Cancer (ORIGAMI-1 right-
sided)
US TREMFYA (guselkumab) 	US RYBREVANT (amivantamab) 	US STELARA (ustekinumab) 	TREMFYA (guselkumab) 	JNJ-4804 Co-antibody Therapeutic
EU Crohn's Disease (GALAXI) 	EU Subcutaneous (PALOMA-3) 	EU Pediatric Ulcerative Colitis
(UNIFY JR)
Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis (AFFINITY)
US TREMFYA (guselkumab) 	IMBRUVICA (ibrutinib) 	US STELARA (ustekinumab) 	icotrokinra 	icotrokinra
Pediatric Juvenile Psoriatic
Arthritis
EU Frontline MCL (Triangle) 	Pediatric Crohn's Disease (UNITI
JR)
Psoriasis (ICONIC-LEAD, ICONIC-
TOTAL)
Ulcerative Colitis (ANTHEM)
TREMFYA (guselkumab) 	US icotrokinra 	icotrokinra 	nipocalimab Combination Therapy
EU Ulcerative Colitis (QUASAR) 	EU Psoriasis (ICONIC) 	Psoriasis (ICONIC-Advance1/2) 	Rheumatoid Arthritis (DAISY)
STELARA (ustekinumab) 	aticaprant
EU Pediatric Crohn's Disease (UNITI
JR)
Adjunctive Treatment for Major
Depressive Disorder with
Anhedonia (Ventura 1)
RPGR Gene Therapy
Retinitis Pigmentosa (LUMEOS)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2025*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and
assets and does not guarantee continued investment. This information is as of "&Date&" to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
1 In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets
and does not guarantee continued investments. This information is as of January 22, 2025 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.
= Achieved
Anhedonia (Ventura)

-- 31 of 31 --